Emerging Therapies Take Center Stage in Migraine Pipeline Report | Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, and Others

DelveInsight's, "Migraine Pipeline Insight 2023" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Migraine pipeline landscape. It covers the Migraine pipeline drug profiles, including Migraine clinical trials and nonclinical stage products. It also covers the Migraine pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Migraine Pipeline treatment landscape of the report, click here @ Migraine Pipeline Outlook- https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Migraine Overview
Migraine is a neurological pain condition that affects millions of people. It is the most common neurological disease that has significant effects on the brain and consequently on behaviors associated with repeated migraine attacks. The stress of migraine is associated with premigraine, intermigraine, and postmigraine processes.

Key Takeaways from the Migraine Pipeline Report
• DelveInsight's Migraine pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Migraine treatment.
• The leading Migraine Companies include Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, and others.
• Promising Migraine Pipeline Therapies includes Lasmiditan, Sumavel DosePro, Sumatriptan, ZNS, Eptinezumab, AMG334, Oral Prophylactic, Frovatriptan 2.5 mg, topiramate, Almotriptan Malate, and others.
• On March 2023, the U.S. Food and Drug Administration (FDA) approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptide (CGRP) receptor antagonist nasal spray for the acute treatment of migraine with or without aura in adults. In its pivotal Phase 3 study, ZAVZPRET was statistically superior to placebo on the co-primary endpoints of pain freedom and freedom from most bothersome symptoms at two hours post-dose. The pivotal study also demonstrated pain relief as early as 15 minutes in a prespecified secondary endpoint versus placebo.

• In August 2022, Axsome Therapeutics, Inc. initiated a trial titled, "An Open-Label, Multiple-Dose Evaluation ofthe Efficacy and Safety of AXS-07 (Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults with a PriorInadequate Response to an Oral CGRP Inhibitor". This is a multicenter, open-label trial to evaluate the efficacy and safety ofAXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors. Eligible subjects will receiveopen-label AXS-07 for up to 8 weeks for at-home treatment of their next 4 migraine attacks. The trial is currently active with100 participants and is anticipated to be complete by December 2023.

For further information, refer to the detailed Migraine Unmet Needs, Migraine Market Drivers, and Migraine Market Barriers, click here for Migraine Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Migraine Emerging Drugs Profile

• AXS-07: Axsome Therapeutics
AXS-07 is a novel, oral, rapidly absorbed, multi-mechanistic, investigational medicine. AXS-07 consists of MoSEIC (Molecular Solubility Enhanced Inclusion Complex) meloxicam and rizatriptan. AXS-07 is thought to act by inhibiting Calcitonin gene-related peptide (CGRP) release, reversing CGRP-mediated vasodilation, and inhibiting neuroinflammation, pain signal transmission, and central sensitization. Meloxicam is a new molecular entity for migraine enabled by MoSEIC™ technology, which results in rapid absorption of meloxicam while maintaining a long plasma half-life. AXS-07 is currently being developed for the acute treatment of migraine. The product is in the NDA submitted phase of development.

• STS-101: Satsuma Pharmaceuticals
STS101 combines the Satsuma powder technology with an easy-to-use nasal delivery device to create a reliable and convenient DHE product potentially able to provide the unique clinical advantages of DHE while overcoming the shortcomings of existing DHE products. TS101 has a number of key advantages that we believe may provide significant benefits over other acute treatments for migraine and result in robust and consistent clinical performance. These advantages arise from our proprietary dry-powder formulation, which incorporates a mucoadhesive drug carrier and engineered drug particle technologies, and our proprietary nasal delivery device. STS101 is an investigational product that is currently being evaluated in Phase 3 clinical trials for the acute treatment of migraine and is not approved by the U.S. Food and Drug Administration.

• Zavegepant: Biohaven Pharmaceuticals
Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.

• TNX1900: Tonix Pharmaceuticals
TNX-1900(Oxytocin), Tonix's proprietary potentiated intranasal oxytocin is in the pre-Investigational New Drug (IND) stage and is currently being studied as a candidate for prophylaxis of chronic migraine. Oxytocin is a naturally occurring human hormone that acts as a neurotransmitter in the brain. In clinical and preliminary research, it has been observed that increased oxytocin levels can relieve headaches. When oxytocin is delivered via the nasal route, it results in enhanced binding to receptors on neurons in the trigeminal system, inhibiting transmission of pain signals. Intranasal oxytocin has been well tolerated in several clinical trials in adults and children and has been shown to block calcitonin gene-related peptide (CGRP) release in animals, a pathway known to be critical to the pathogenesis of migraine attacks. TNX-1900 is believed to interrupt pain signals at the trigeminal ganglia by suppressing electrical impulses, a potentially different activity than drugs that just block CGRP. TNX-1900 is an investigational new drug and has not been approved for any indication.

Request a sample and discover the recent advances in Migraine Ongoing Clinical Trial Analysis and Medications, click here @ Migraine Treatment Landscape- https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Migraine Pipeline Therapeutics Assessment
There are approx. 30+ key companies which are developing the therapies for Migraine. The companies which have their Migraine drug candidates in the most advanced stage, i.e. phase III include, Novartis.

Dive deep into rich insights for drugs for Migraine Pipeline, click here @ Migraine Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Migraine Pipeline Report
• Coverage- Global
• Migraine Companies- Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity, AbbVie, Pulmatrix, AEON Biopharma, Eli Lilly and Company, Trevena, Xoc Pharmaceuticals, Pharmaleads, Pear Therapeutics, and others.
• Migraine Pipeline Therapies- Lasmiditan, Sumavel DosePro, Sumatriptan, ZNS, Eptinezumab, AMG334, Oral Prophylactic, Frovatriptan 2.5 mg, topiramate, Almotriptan Malate, and others
• Migraine Pipeline Segmentation: Product Type, Molecule Type, Mechanism of action, Route of administration

Got Queries? Find out the related information on Migraine Mergers and acquisitions, Migraine Licensing Activities @ Migraine Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/migraine-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Migraine: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Migraine- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. AXS-07: Axsome Therapeutics
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase III)
11. STS-101: Satsuma Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. TNX1900: Tonix Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Migraine Key Companies
21. Migraine Key Products
22. Migraine - Unmet Needs
23. Migraine - Market Drivers and Barriers
24. Migraine - Future Perspectives and Conclusion
25. Migraine Analyst Views
26. Migraine Key Companies
27. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States

This release was published on openPR.